This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): silodosin, KMD-3213, Urief (Japan), Silodyx (EU), Urorec (EU), KSO-0400
Description: Rapaflo is an orally active alpha(1)-adrenoceptor antagonist.
Kissei and Daiichi
In March 2001, Kissei entered into a joint drug development agreement with Daiichi Pharmaceutical. for Rapaflo. The drug is marketed in Japan in cooperation with Daiichi Sankyo Pharmaceutical Co.
Watson and Kissei
In April 2004, Watson entered into an exclusive licensing agreement with Kissei to develop and market Rapaflo, Kissei's agent for the treatment of the signs and symptoms of benign prostatic hyperplasia. Under the agreement, Watson has exclusive rights to develop and commercialize silodosin in the U.S., Canada, and Mexico. Kissei will receive payments based on achievement of certain milestones, and royalties based on Watson's sales of the product. Watson will be responsible for conducting Phase III clinical studies and preparing and submitting the New Drug Application (NDA) to support FDA approval.
In January 2013, Watson changed its name to Actavis.
Recordati and Kissei
In December 2004, Recordati into...See full deal structure in Biomedtracker
Partners: Kissei Pharmaceutical Co., Ltd Recordati SpA Daiichi Sankyo Co., Ltd. Almirall Prodesfarma, S.A. Takeda Pharmaceutical Company Ltd Zambon Company S.p.A.
Additional information available to subscribers only: